The advancement in stroke therapy has significantly decreased the mortality rate of stroke. Nevertheless, Post-Stroke Epilepsy (PSE) continues to pose a substantial clinical challenge for survivors, and there is currently no established treatment protocol[1]. In addition, there are various pharmacokinetic and pharmacodynamic interactions between anti-seizure medications(ASMs) and medications used for managing epilepsy comorbidities (e.g., hypertension, type 2 diabetes, atherosclerosis), which are complex and not fully elucidated in clinical practice[2].
12
ENE
ENE
0